EPIVIRHBV (GlaxoSmithKline LLC)
Welcome to the PulseAid listing for the EPIVIR drug offered from GlaxoSmithKline LLC. This Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | GlaxoSmithKline LLC |
NON-PROPRIETARY NAME: | lamivudine |
SUBSTANCE NAME: | LAMIVUDINE |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Nucleoside Analog [Chemical/Ingredient],Nucleoside Reverse Transcriptase Inhibitors [MoA] |
ROUTE: | ORAL |
DOSAGE FORM: | TABLET, FILM COATED |
MARKETING CATEGORY NAME: | NDA |
START MARKETING DATE: | 1998-12-17 |
END MARKETING DATE: | 0000-00-00 |
EPIVIR HBV HUMAN PRESCRIPTION DRUG Details:
Item Description | EPIVIR HBV from GlaxoSmithKline LLC |
LABELER NAME: | GlaxoSmithKline LLC |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 100(mg/1) |
START MARKETING DATE: | 1998-12-17 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0173-0662_3f46fa8c-6d88-4d25-b097-58400b784b31 |
PRODUCT NDC: | 0173-0662 |
APPLICATION NUMBER: | NDA021003 |
Other LAMIVUDINE Pharmaceutical Manufacturers / Labelers: